Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis

Aim. In this paper, we aimed to develop and validate a risk prediction method using independent prognosis genes selected robustly in prostate cancer. Method. We considered 723 samples obtained from TCGA (the Cancer Genome Atlas), GSE46602, and GSE21032. Prostate cancer prognosis-related genes with P...

Full description

Saved in:
Bibliographic Details
Main Authors: Yutao Wang, Jiaxing Lin, Kexin Yan, Jianfeng Wang
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:International Journal of Genomics
Online Access:http://dx.doi.org/10.1155/2020/1097602
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832559218678300672
author Yutao Wang
Jiaxing Lin
Kexin Yan
Jianfeng Wang
author_facet Yutao Wang
Jiaxing Lin
Kexin Yan
Jianfeng Wang
author_sort Yutao Wang
collection DOAJ
description Aim. In this paper, we aimed to develop and validate a risk prediction method using independent prognosis genes selected robustly in prostate cancer. Method. We considered 723 samples obtained from TCGA (the Cancer Genome Atlas), GSE46602, and GSE21032. Prostate cancer prognosis-related genes with P<0.05 were selected using Univariable Cox regression analysis. We then built the lowest AIC (Akaike information criterion score) optimal gene model using the “Rbsurv” package in TCGA train set. The coefficients were obtained by Multivariable Cox regression analysis. We named the new prognosis method CMU5. The CMU5 risk score was verified in TCGA test set, GSE46602, and GSE21032. Results. FAM72D, ARHGAP33, TACR2, PLEK2, and FA2H were identified as independent prognosis factors in prostate cancer patients. We built the computing model as follows: CMU5 risk score = 1.158∗FAM72D + 1.737∗ARHGAP33 − 0.737∗TACR2 − 0.651∗PLEK2 − 0.793∗FA2H. The AUC of DFS was 0.809 in the train set (274 samples), 0.710 in the test set (273 samples), and 0.768 in the complete set (547 samples). The benign prediction capacity of CMU5 was verified by GSE46602 (36 samples; AUC=0.6039) and GSE21032 GPL5188 (140 samples; AUC=0.7083). Using the cut-off point of 2.056, a significant difference was shown between high- and low-risk groups. Conclusion. A prognosis-related risk score formula named CMU5 was built and verified, providing reliable prediction of prostate cancer outcome. This signature might provide a basis for individualized treatment of prostate cancer.
format Article
id doaj-art-7630d248886c4960887eb74a2ff09f84
institution Kabale University
issn 2314-436X
2314-4378
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series International Journal of Genomics
spelling doaj-art-7630d248886c4960887eb74a2ff09f842025-02-03T01:30:30ZengWileyInternational Journal of Genomics2314-436X2314-43782020-01-01202010.1155/2020/10976021097602Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival AnalysisYutao Wang0Jiaxing Lin1Kexin Yan2Jianfeng Wang3Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaAim. In this paper, we aimed to develop and validate a risk prediction method using independent prognosis genes selected robustly in prostate cancer. Method. We considered 723 samples obtained from TCGA (the Cancer Genome Atlas), GSE46602, and GSE21032. Prostate cancer prognosis-related genes with P<0.05 were selected using Univariable Cox regression analysis. We then built the lowest AIC (Akaike information criterion score) optimal gene model using the “Rbsurv” package in TCGA train set. The coefficients were obtained by Multivariable Cox regression analysis. We named the new prognosis method CMU5. The CMU5 risk score was verified in TCGA test set, GSE46602, and GSE21032. Results. FAM72D, ARHGAP33, TACR2, PLEK2, and FA2H were identified as independent prognosis factors in prostate cancer patients. We built the computing model as follows: CMU5 risk score = 1.158∗FAM72D + 1.737∗ARHGAP33 − 0.737∗TACR2 − 0.651∗PLEK2 − 0.793∗FA2H. The AUC of DFS was 0.809 in the train set (274 samples), 0.710 in the test set (273 samples), and 0.768 in the complete set (547 samples). The benign prediction capacity of CMU5 was verified by GSE46602 (36 samples; AUC=0.6039) and GSE21032 GPL5188 (140 samples; AUC=0.7083). Using the cut-off point of 2.056, a significant difference was shown between high- and low-risk groups. Conclusion. A prognosis-related risk score formula named CMU5 was built and verified, providing reliable prediction of prostate cancer outcome. This signature might provide a basis for individualized treatment of prostate cancer.http://dx.doi.org/10.1155/2020/1097602
spellingShingle Yutao Wang
Jiaxing Lin
Kexin Yan
Jianfeng Wang
Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
International Journal of Genomics
title Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
title_full Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
title_fullStr Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
title_full_unstemmed Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
title_short Identification of a Robust Five-Gene Risk Model in Prostate Cancer: A Robust Likelihood-Based Survival Analysis
title_sort identification of a robust five gene risk model in prostate cancer a robust likelihood based survival analysis
url http://dx.doi.org/10.1155/2020/1097602
work_keys_str_mv AT yutaowang identificationofarobustfivegeneriskmodelinprostatecancerarobustlikelihoodbasedsurvivalanalysis
AT jiaxinglin identificationofarobustfivegeneriskmodelinprostatecancerarobustlikelihoodbasedsurvivalanalysis
AT kexinyan identificationofarobustfivegeneriskmodelinprostatecancerarobustlikelihoodbasedsurvivalanalysis
AT jianfengwang identificationofarobustfivegeneriskmodelinprostatecancerarobustlikelihoodbasedsurvivalanalysis